Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alnylam Pharmaceuticals has announced a ...
NEWARK, Calif., May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral ...
Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results